Supplementary protection
LT - Pakeistieji 1,2,3,4- tetrahidrociklopenta[b]indol-3-ilacto rūgšties dariniai, tinkami autoimuninių ir uždegiminių sutrikimų gydymui
EN - SUBSTITUTED 1,2,3,4- TETRAHYDROCYCLOPENTA[b]INDOL-3-YL) ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS
SPC
| (11) |
Number of the document |
|
| (68) |
Number of the document |
2326621
|
| (21) |
Application number for Supplementary Protection Certificate |
PA 2024 524 |
| (22) |
Date of filing the application |
2024-07-18 |
| (41) |
Date of publication of the application |
2024-08-12 |
|
Date of publication of SPC |
|
| (24) |
Date of coming into effect of SPC |
|
Applicant
| (71) |
Arena Pharmaceuticals, Inc.,
66 Hudson Boulevard East, NY 10001-2192, New York,
US
|
Grantee
| (73) |
Arena Pharmaceuticals, Inc.,
66 Hudson Boulevard East, NY 10001-2192, New York,
US
|
Attorney or representative
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
Number, date and code of the country of origin of the first authorization to place the medicinal or plant protection product on the market within regional economic community
| (93) |
EU/1/23/1790, 2024-02-16
|
Name of the product protected by the basic patent
| (95) |
Etrasimodas, arba farmaciniu požiūriu priimtina jo druska, tokia kaip etrasimodo argininas |
Legal status
|
SPC application published
|
|
